Terkko Navigator / Autoimmunity Reviews

A review and meta-analysis of anti-ribosomal P autoantibodies in systemic lupus erythematosus.

Standardisation of nailfold capillaroscopy for the assessment of patients with Raynaud's phenomenon and systemic sclerosis.

ESTROGEN, ESTROGEN-LIKE MOLECULES AND AUTOIMMUNE DISEASES.

Anti-RNP antibodies delineate a subgroup of myositis: A systematic retrospective study on 46 patients.

Understanding the immunopathogenesis of autoimmune diseases by animal studies using gene therapy: A comprehensive review.

Combination vasodilator therapy improves skin microvascular blood but do not restore endothelial function in systemic sclerosis.

Post-rituximab immunoglobulin M (IgM) hypogammaglobulinemia.

Characterization of auto-immune hepatitis associated with the use of anti-TNFα agents: An analysis of 389 cases in VigiBase.

Interaction between food antigens and the immune system: Association with autoimmune disorders.

Systemic lupus erythematosus associated with thymoma: A fifteen-year observational study in France.

IRAK family in inflammatory autoimmune diseases.

Immune response biomarkers as indicators of sarcoidosis presence, prognosis, and possible treatment: An immunopathogenic perspective.

Diagnosis of gluten-related disorders: A new and challenging public health problem.

Conceptual, statistical and clinical interpretation of results from a systematic review and meta-analysis of prevalence of cervical HPV infection in women with SLE.

Reply to the editor.

Belimumab reduces antiphospholipid antibodies in SLE patients independently of hydroxychloroquine treatment.

Clinical, morphological features and prognostic factors associated with interstitial lung disease in primary Sjӧgren's syndrome: A systematic review from the Italian Society of Rheumatology.

Thermography in systemic sclerosis patients and other rheumatic diseases: Diagnosis, disease activity assessment, and therapeutic monitoring.

Mechanistic classification of immune checkpoint inhibitor toxicity as a pointer to minimal treatment strategies of selected emergent autoimmune disease to further improve survival.

Autoantigenomics: Holistic characterization of autoantigen repertoires for a better understanding of autoimmune diseases.

Giant-cell arteritis associated with myelodysplastic syndrome: French multicenter case control study and literature review.

Targeting CD20 in the treatment of interstitial lung diseases related to connective tissue diseases: A systematic review.

Emerging PD-1 and PD-1L inhibitors-associated myopathy with a characteristic histopathological pattern.

The prevalence of 78 autoimmune diseases in Catalonia (MASCAT-PADRIS Big Data Project).

Enteropathic spondyloarthritis: Results from a large nationwide database analysis.

Interstitial pneumonia with autoimmune features: A single center prospective follow-up study.

Isolated autoimmune adrenocorticotropic hormone deficiency: From a rare disease to the dominant cause of adrenal insufficiency related to check point inhibitors.

Outcomes of limited cutaneous systemic sclerosis patients: Results on more than 12,000 patients from the EUSTAR database.

Subcutaneous immunoglobulin in inflammatory myopathies: efficacy in different organ systems.

Coronary artery disease in systemic lupus: A case-controlled angiographic study.

Complement alternative pathway in ANCA-associated vasculitis: Two decades from bench to bedside.

Serum amyloid A as a marker of disease activity in Giant cell arteritis.

Corticosteroid-sparing benefit of intravenous immunoglobulin in systemic sclerosis-associated myopathy: A comparative study in 52 patients.

Critical role of interleukin (IL)-17 in inflammatory and immune disorders: An updated review of the evidence focusing in controversies.

Systemic sclerosis induced by CNS stimulants for ADHD: A case series and review of the literature.

Multiple sclerosis, the microbiome, TLR2, and the hygiene hypothesis.

Validation of anti-Mi2 autoantibody testing by line blot.

Aetiology and pathogenesis of paraneoplastic autoimmune disorders.

The Giants (biologicals) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis.

Comparative United States autoimmune disease rates for 2010-2016 by sex, geographic region, and race.

Should we combine biologics with methotrexate in axial spondyloarthritis?

Do DMARDs and biologic agents protect from cardiovascular disease in patients with inflammatory arthropathies?

Treatment for refractory lupus nephritis: Rituximab vs triple target therapy.

Magnetic resonance angiography versus 18F-fluorodeoxyglucose positron emission tomography in large vessel vasculitis.

Cannabinoids in the treatment of rheumatic diseases: Pros and cons.

Can we use NOACS in APS?

Does seronegative obstetric APS exist? "pro" and "cons".

Biosimilars vs originators: Are they the same?

Can we wean patients with inflammatory arthritis from biological therapies?

Is there today a place for corticosteroids in the treatment of scleroderma?